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ApoptosisBax-mediated cell death by inhibiting the initial Bax conformational change that
converts cytosolic Bax into a pro-apoptotic protein. PrP is mostly a glycophosphatidylinositol-anchored cell
surface protein but it is also retrotranslocated into cytosolic PrP (CyPrP) or can become a type 1 or type 2
transmembrane protein. To determine the form and subcellular location of the PrP that has anti-Bax function,
we co-expressed various Syrian hamster PrP (SHaPrP) mutants that favour speciﬁc PrP topologies and
subcellular localization with N-terminally green ﬂuorescent protein tagged pro-apoptotic Bax (EGFP-Bax) in
MCF-7 cells and primary human neurons. Mutants that generate both CyPrP and secreted PrP (SecPrP) or only
CyPrP have anti-Bax activity. Mutants that produce CtmPrP or NtmPrP lose the anti-Bax activity, despite their
ability to also make SecPrP. Transmembrane-generating mutants do not produce CyPrP and both normal and
cognate mutant forms of CyPrP rescue against the loss of anti-Bax activity. SecPrP-generating constructs also
produce non-membrane attached SecPrP. However, this form of PrP has minimal anti-Bax activity. We
conclude that CyPrP is the predominant form of PrP with anti-Bax function. These results imply that the
retrotranslocation of PrP encompasses a survival function and is not merely a pathway for the proteasomal
degradation of misfolded protein.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Prion protein (PrP) is ubiquitously expressed as a glycosylpho-
sphatidylinositol (GPI)-anchored cell surface protein in mammals [1].
Recently, growing evidence suggests that PrP plays a protective role in
cells [2,3]. In vivo, PrP protects neurons from Doppel-mediated cell
death, N-terminally truncated PrP toxicity, focal cerebral ischemia and
kainic acid-induced seizures [4–9]. In vitro, mouse hippocampal cell
lines derived from Prnp−/− mice undergo serum-deprivation mediated
apoptosis more readily than those derived from Prnp+/+ mice, and this
effect is rescued by the ectopic expression of either PrP or Bcl-2 [10].
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l rights reserved.(H2O2) and copper overload [11]. In MCF-7 breast carcinoma cells, PrP
protects against tumour necrosis factor-α (TNFα)- and anti-cancer
drug-induced apoptosis [12–14]. More speciﬁcally, PrP protects
against Bax-mediated cell death in primary human neurons and
MCF-7 cells [15,16]. Furthermore, the role of PrP against Bax is likely
physiologically relevant because endogenously expressed PrP inhibits
endogenous Bax activation in serum-deprived hippocampal cell lines,
antisense PrP constructs increase Bax-mediated cell death in primary
human neurons, and PrP prevents staurosporin-induced endogenous
Bax activation in MCF-7 cells [15,16]. In vivo, expression of Bcl-2 and
elimination of Bax expression partially inhibit Doppel-mediated
cerebellar Purkinge cell death in the absence of PrP indicating that
PrP's protective role involves blocking Bax activation [17,18]. In MCF-7
cells, human primary neurons, and hippocampal cell lines, PrP
achieves its anti-Bax function by preventing the conformational
change of Bax that converts inactive cytosolic Bax into the pro-
apoptotic Bax known to undergo oligomerisation and translocation to
the mitochondria, resulting in cytochrome c release and caspase
activation [16]. Thus, PrP acts at the very ﬁrst step of Bax activation, as
do several other natural Bax inhibitors [19]. Yet, the exact mechanism
by which PrP inhibits Bax is unknown. The anti-Bax function of PrP
does not require other members of the Bcl-2 family of proteins since
PrP prevents Bax-mediated cell death in Saccharomyces Cerevisiae
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localized in the cytosol [19], but other Bax inhibitors, such as the
bifunctional apoptosis regulator (BAR) and Bax inhibitor 1 (BI-1)
proteins [21,22], exert their function from the endoplasmic reticulum
(ER), here we investigate the location of PrP's anti-Bax function as a
step to elucidate its underlying molecular mechanism.
While PrP accumulates mostly at the cell surface as a GPI-anchored
protein (SecPrP), a small amount is cytosolic [23–26]. Cytosolic PrP
arises from retrotranslocation of endogenously expressed PrP from
the ER into the cytosol (CyPrP) of human neurons [27] or from
incomplete translocation into the ER due to a weak signal peptide (SP-
CyPrP) [28,29]. The CyPrP has been attributed both toxic and
protective functions. Ectopically expressed CyPrP is toxic to mouse
neuroblastoma N2a cells and cerebellar neurons [30,31], but protects
human neurons against Bax-mediated cell death [27]. The human
familial PrPmutations associatedwith Creutzfeldt–Jakob disease (CJD)
have defective retrotranslocation and lose their anti-Bax function in
human neurons and in MCF-7 cells [32]. However, co-expressed
normal or cognate mutant CyPrPs rescue against the loss of anti-Bax
function in these cells.
On the other hand, PrP also contains a highly conserved trans-
membrane domain [33,34]. CtmPrP, which has the COOH-terminus in
the lumen and NH2-terminus in the cytosol, and NtmPrP, with the
COOH-terminus in the cytosol and NH2-terminus in the lumen, have
been well described by in vitro translation studies [35–39]. The ability
of PrP to adoptmultiple topologies depends on both the signal peptide
and the transmembrane region [35,36,40]. Mutations that alter the
charge or hydrophobicity of the amino acid sequence in either of these
regions can inﬂuence the ﬁnal topology of PrP [35,36]. Changes in the
N-terminal signal peptide affect the efﬁciency of the protein to be
targeted to the translocon for translocation into the ER, while
alterations of the transmembrane region inﬂuence the integration of
the protein into the membrane [35]. Overexpression of CtmPrP in
transgenicmice causes spontaneous neurodegeneration, a feature that
is also observed in Gerstmann–Sträussler–Scheinker (GSS) disease
associated with the A117V PrP mutation [37,39]. Furthermore, familial
PrP mutations of the GPI-anchor signal peptide favour a rapid
translocation of PrP to the cell surface where it incorporates as CtmPrP
[41]. Here, we opted to use constructs that preferentially generate the
various topologies of PrP to assess the form and the location of PrP
with anti-Bax function.
2. Materials and methods
2.1. Antibodies and reagents
Anti-prion mouse monoclonal 3F4 antibody recognizing residues
109–112 of full lengthwild type (WT) Syrian hamster PrP (SHaPrP) was
puriﬁed frommedia of cultured hybridoma cells [42]. Anti-prionmouse
monoclonal 13A5 antibody recognizing residues 138–141 of full length
WT SHaPrP was prepared in the form of ascites and kindly provided by
Dr. Vishwanath R. Lingappa (University of California San Francisco, CA,
USA) [37,38,43,44]. Anti-prion rabbit polyclonal R155 antiserum
directed against residues 36–56 of full lengthWT SHaPrPwas produced
in our laboratory [15]. Anti-GFP and anti-β-actinmonoclonal antibodies
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and
Sigma-Aldrich (St. Louis, MO), respectively. Anti-Bip (H-129) polyclonal
antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). Monoclonal 2D2 and polyclonal N20 anti-Bax antibodies were
purchased from Trevigen (Gaithersburg, MD) and Santa Cruz Biotech-
nology (Santa Cruz, CA), respectively. Anti-Bcl-2 monoclonal (100) and
polyclonal (N19) antibodies were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA). Horseradish peroxidase (HRP)-conjugated
anti-mouse IgG and IgM antibodies were purchased from Jackson
laboratories (BarHarbor,ME). EndoglycosidaseH (EndoH) andpeptide:
N-Glycosidase F (PNGase F) enzymes were purchased from NewEngland Biolabs (Ipswich,MA). Recombinant PrP (rPrP) and Bax protein
were a kind gift from Dr. Witold Surewicz (Case Western Reserve
University, OH, USA) and Dr. Jean-Claude Martinou (University of
Geneva, Switzerland), respectively. Recombinant Bcl-2 was purchased
from Cedarlane Lab. Ltd (Hornby, ON).
2.2. Cloning
All topological constructs including the WT SHaPrP, with the
exception of PrPΔGPI, were generously provided by Drs. Vishwanath
R. Lingappa (University of California San Francisco, CA, USA) and
Ramanujan S. Hegde (NIH, MD, USA) in the pcDNA3.1 vector [35,37].
The constructs were transferred by using various compatible restric-
tion sites under the cytomegalovirus (CMV) promoter into the bigenic
pBudCE4.1 vector (Invitrogen, Burlington, ON) expressing EGFP or
EGFP-Bax under the EF-1α promoter (pBud-EGFP or pBud-EGFP-Bax),
as described previously [32]. The PrP was cloned under the CMV
promoter in pBud-EGFP or pBud-EGFP-Bax to generate pBud-EGFP/
PrP or pBud-EGFP-Bax/PrP constructs. WT SHaPrP, and the mutants
A120L, N4 A120L, N7a ΔSTE, and N7a A120L were released with the
NheI and EcoRI sites and inserted using the XbaI and EcoRI sites of
pBud-EGFP and pBud-EGFP-Bax. The AV3mutant cDNAwas subcloned
using the HindIII and EcoRI sites. The KH→II mutation was subcloned
using the SalI and EcoRI sites. Mutants ΔSTE, Opn-PrP, Prl-PrP, and
MH2M G123P were released with the HindIII and XhoI and subcloned
by inserting into the HindIII and SalI sites. pBud-EGFP/PrPΔGPI was
generated by using pBud-EGFP/SHaPrP as template for PCR reaction
with the upstream primer 5′TTAGTAGGTCACCGAA TTCAGACATGATA-
AGATACATTG3′ and the downstream primer 5′TCTCACGGTCACCTTA
GGACCTTCTTCCA TCGTAGTAGGCC3′, both containing a BstEII restric-
tion enzyme site at the 5′ end. The PCR product was digested with
BstEII to produce sticky ends and ligated to circularize the plasmid.
pBud-EGFP-Bax/PrPΔGPIwas constructed by subcloning PrPΔGPI from
pBud-EGFP/PrPΔGPI into pBud-EGFP-Bax vector under the CMV
promoter using HindIII and EcoRI sites.
To assess the expression of each mutant under the CMV promoter
in MCF-7 cells, the episomal vector pCep4β (Invitrogen, Burlington,
ON, Canada)was used [45].WT SHaPrP, andmutants A120L, N4 A120L,
N7a ΔSTE, and N7a A120L were subcloned into NheI and XhoI sites
and mutants MH2M G123P, ΔSTE, Opn-PrP, and Prl-PrP were
subcloned downstream CMV promoter using HindIII and XhoI sites.
For the generation of pCep4β-KH→II, AV3, and PrPΔGPI, the cDNA
fragment of each mutant was ﬁrst ampliﬁed by PCR using the
upstream primer 5′ACCAAAGCTTATGGCAACCTTAGCTACTGGC3′, and
downstream primers 5′GTATCTCG AGTCATCCCACCATCAGGAAGA3′
for KH→II and AV3 or 5′ ACCGCTCGAGTT AGGACCTTCTTCCATCGTA3′
for PrPΔGPI. The PCR products were subcloned into the HindIII and
XhoI sites of pCep4β.
For the rescue of anti-Bax function in MCF-7 cells and primary
human neurons, the CyPrP, CyPrPKH→II and CyPrPSHaAV3 were ﬁrst
ampliﬁed by PCR reaction using pBud-EGFP/PrPΔGPI, pBud-EGFP/
PrPKH→II, and pBud-EGFP/PrPSHaAV3 as templates, respectively,
with the upstream primer 5′GA CCCAAGCTTACGATGAAGAAGCGGC3′
and the downstream primer 5′GGCGCTTCTT CATCGTAAGCTTGGG-
TC3′. The CyPrPs were subcloned into the HindIII and BamHI restric-
tion sites of pCep4β.
2.3. Cell culture and transfections
Humanprimary neuronswere cultured as described [46,47].MCF-7
human carcinoma cells and N2amouse neuroblastoma cells were both
obtained from ATCC (Manassas, VA) and maintained in Dulbecco's
Modiﬁed EagleMedium (DMEM), supplementedwith 10% fetal bovine
serum.
For transfections of the human neurons, the cells were plated at
a density of 3×106 cells/mL onto poly-L-lysine (20 µg/mL; Sigma-
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Neurons were transfected with 1 µg DNA/shot using the Helios Gene
Gun system from Biorad (Mississauga, ON) at a shooting pressure of
110 psi according to the manufacturer's protocol. The preparation
of transfection cartridges was carried out as described previously
[16,32].
For transfections of the N2a and MCF-7 cells, cells were grown to
90% conﬂuency and transfected with 4–5 µg DNA per 1.0×106 cells,
using Lipofectamine 2000 reagent (Invitrogen, Burlington, ON).
Plasmid DNA was extracted with the alkaline lysis method and
puriﬁed with the UltraClean Endotoxin removal kit (MoBio Lab,
Carlsbad, CA). Alternatively, MCF-7 cells at 60% conﬂuency were
transfected with the Helios Gene Gun System as described above for
the human neurons, except with a shooting pressure of 220 psi. When
MCF-7 cells were co-transfected with two constructs, the ratio of the
constructs was 1:3 pCepP4β-EGFP: pCep4β-SHaPrP (or mutants) for
PrP expression studies, or 1:3 pBud-EGFP-Bax: pCep4β-PrP (or CyPrP
or PrPΔGPI) for functional studies. The transfection efﬁciency was
assessed by counting the number of EGFP-positive green cells versus
the total number of cells stained with Hoescht and expressing this
ratio as a percentage. N2a cells were transfected at 90–100% efﬁciency
with lipofectamine 2000, MCF-7 cells were transfected at 30%
transfection efﬁciency using lipofectamine 2000 or Gene Gun, and
the human neurons were transfected at less than 0.01% transfection
efﬁciency. Previously, EGFP-Bax overexpression and activation have
been conﬁrmed by ﬂuorescence microscopy of EGFP, immunoﬂuor-
escence microscopy with anti-active 6A7 Bax antibodies, and
immunoprecipitation of active Bax with 6A7 from subcellular
cytosolic and membrane fractions. The EGFP-Bax translocates to the
mitochondria and is accompanied by the release of cytochrome c and
cell death as is observed for endogenous Bax activationwith apoptotic
insults [16].
2.4. Western blot analysis
Transfected N2a and MCF-7 cells were harvested with Nonidet-P
40 (NP-40) lysis buffer (150 mM NaCl, 50 mM Tris–HCl pH 8.0, 5 mM
EDTA pH8.0, 1% NP-40, and 1× protease inhibitors) 48 h following
transfection and placed on ice for 15 min to allow complete lysis. Cell
lysates were centrifuged at 13,000 ×g at 4 °C for 15min to separate the
detergent soluble and insoluble fractions. The NP-40 insoluble fraction
was subsequently solubilized in 2% SDS. For the immunodetection of
proteins, samples were quantiﬁed with BCA protein assays (Pierce,
Rockford, IL) and 100 µg proteins of the NP-40 soluble and insoluble
fractions were precipitatedwith 4 volumes of methanol for at least 2 h
at −20 °C. The protein precipitates were solubilized in SDS gel loading
buffer (0.5% SDS, 1.25% β-mercaptoethanol, 4.0% glycerol, 0.01%
bromophenol blue, and 15.0 mM Tris–HCl pH 6.8) and brieﬂy boiled
prior to loading onto a 12–15% SDS-PAGE gel. The separated proteins
were transferred to Immobilon polyvinylidene diﬂuoride (PVDF)
membrane (Millipore, Bedford, MA). The membranes were blocked
with 6% non-fat milk in TBS-T (10 mM Tris–HCl pH 7.4, 135 mM NaCl,
0.1% Tween-20), followed by incubations in 1:1000 3F4 anti-PrP or
1:800 13A5 anti-PrP antibodies for SHaPrP detection, 1:1000 anti-GFP
antibodies or 1:2000 anti-β-actin antibodies. The blots were incu-
bated with secondary anti-mouse IgG and IgM antibodies conjugated
to horseradish peroxidase (1:5000 to 1:10000). Proteins were
detected by chemiluminescent development with ECL reagents from
Amersham Bioscience (Baie d'Urfe, QC) or Millipore (Bedford, MA),
and exposed to Kodak Biomax MR ﬁlm (Toronto, ON) for visualization
of immunoreactive bands.
2.5. Deglycosylation of PrP
Cells were transfected with either pBud-EGFP-SHaPrP, pBud-EGFP-
A120L, or pBud-EGFP-N7a A120L and harvested with NP-40 lysisbuffer 48 h following transfection. One hundred micrograms of
protein from each condition was subjected to brief boiling in the
presence of 0.5% SDS and 1× protease inhibitors, then treated with
either 250 U of PNGase F or Endo H according to the manufacturer's
instructions (New England Biolabs, Pickering, Ontario, Canada) for
18 h at 37 °C. Following treatments, the proteins were precipitated
overnight with 4 volumes of methanol at −20 °C prior to western
blotting analyses as described above.
2.6. Isolation of membranes and topological assays
Forty-eight hours following transfection, the MCF-7 cells were
homogenized in homogenizing buffer (250 mM sucrose (w/v),
100 mM KCl, 5 mM MgAc2, and 50 mM HEPES, pH7.5) with a
Dounce tissue grinder. The unbroken cells and cell nuclei were
removed by a brief centrifugation at 2000 ×g at 4 °C for 10 min. The
resulting supernatant was centrifuged at 100,000 ×g at 4 °C for
30 min to pellet the crude membrane fraction. The pelleted
membrane fraction was washed gently twice with homogenizing
buffer before resuspending in fresh homogenizing buffer lacking
protease inhibitors. The membrane suspension was divided into four
equal aliquots: one left untreated, two treated with 0.25 mg/mL
Proteinase K (PK) for 1 h at 0 °C, and one treated with PK in the
presence of 0.5% Triton X-100. PK activity was irreversibly inhibited
by the addition of 0.5 M PMSF (ﬁnal concentration). Where
indicated, the extracts were treated with PNGase F thereafter for
12 h at 37 °C. Proteins were precipitated with 4 volumes of methanol
for at least 2 h at −20 °C. The protein precipitates were solubilized in
SDS gel loading buffer prior to Western blotting analyses as des-
cribed above.
2.7. Determination of retrotranslocated PrP
Subcellular fractionation was performed as described above with
some modiﬁcations. Brieﬂy, 24 h following transfection with
pCep4β-PrP or mutant PrP, MCF-7 cells were treated with 5 µg/mL
brefeldin A (BFA) (Sigma) and 0.25 µM epoxomycin (BioMol,
Plymouth Meeting, PA) for 20 h. Cells were homogenized in the
Tris–Tricine homogenization buffer (8% sucrose (w/v), 20 mM HCl–
Tricine, pH7.8, and 1 mM EDTA) with a Dounce tissue grinder. The
unbroken cells and cell nuclei were removed by a brief centrifuga-
tion at 2000 ×g at 4 °C for 10 min. The resulting supernatant was
centrifuged at 100,000 ×g at 4 °C for 30 min to separate the cytosolic
(supernatant) and membrane (pellet) fractions. The cytosolic frac-
tions were precipitated overnight with 4 volumes methanol before
western blot analysis. The membrane fractions were washed twice
with Tris–Tricine homogenization buffer to remove traces of
cytosolic proteins and then solubilized in lysis buffer (150 mM
NaCl, 2 mM EDTA, 0.5% Triton X-100 (v/v), 0.5% sodium deoxycholate
(w/v), and 50 mM Tris–HCl, pH7.5) prior to methanol precipitation
for western blot analyses.
2.8. Cell death measurements
Cell death of transfected human neurons and MCF-7 cells was
assessed 20 h following transfection. Brieﬂy, 20 min prior to 20 h
following transfection,1 µg/mL Hoescht 33342were added to the cells
as a DNAmarker. At the 20 h time point, cells were either ﬁxedwith 4%
paraformaldehyde and 4% sucrose in PBS for 20 min at room
temperature before mounting onto glass slides, or were counted
live. Cell death was assessed by counting EGFP-positive cells
displaying condensed (in both MCF-7 cells and human neurons) and
fragmented (in human neurons) chromatin visualized by Hoescht
stain versus the total number of EGFP-positive cells. For each
condition, at least 200 cells were counted in at least 3 independent
experiments.
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Cultured media from transfected N2a cells and MCF-7 cells were
collected 48 h after transfection and centrifuged brieﬂy at 2000 ×g to
remove ﬂoating cells and debris. The supernatant was transferred to a
new tube and the proteins were solubilized in RIPA buffer (750 mM
NaCl, 5% NP-40, 2.5% sodium deoxycholate, 0.5% SDS, 500 mM Tris
pH8.0, and 1× protease inhibitors). Following pre-clearance with
protein-A Sepharose (Sigma), PrP was immunoprecipitated with 1/
100 dilution of anti-PrP polyclonal R155 antisera, and the immuno-
precipitated product was detected using anti-PrP monoclonal 13A5
antibodies by western blotting as described above.
2.10. Anti-Bax function of recombinant PrP and secreted PrP
MCF-7 cells were transfected with pCep4β-EGFP or pCep4β-
PrPΔGPI (ΔGPI). Forty-eight hours following transfection, fresh
media were added to transfected cells, collected after 6 h and
centrifuged for 5 min at 2000 ×g. For immunodepletion, protein A or
protein A coated with the polyclonal R155 antibody against PrP were
added to the recuperated media and incubated overnight under
rotation at 4 °C. Beads were removed and the recuperated media were
added to pBud-EGFP-Bax-transfected MCF-7 cells. Alternatively, E. coli
generated recombinant PrP (rPrP) was added to the culture media of
pBud-EGFP-Bax-transfected MCF-7 cells. Cell death under each
condition was assessed 20 h after the treatment as described above.
2.11. Co-immunoprecipitation of PrP with Bax
PrP, Bax and Bcl-2 proteins were in vitro translated using the TNT
Coupled Reticulocyte Lysate Systems from Promega (Madison, WI).
Twenty-ﬁve nanograms of recombinant Bax, 25 ng of recombinant
PrP and 25 ng of recombinant Bcl-2 were mixed to assess co-
immunoprecipitation. Human brain proteins were extracted in a
homogenization buffer (150 mM KCl, 5 mM MgCl2, 1 mM EDTA,
10 mM HEPES pH 7.2, 0.2% NP-40) and homogenized with 30 strokes
in a Potter–Elvehjem homogenizer. After a centrifugation at
13,000 ×g for 10 min at 4 °C, 500 µg of proteins from the supernatant
was used for co-immunoprecipitation experiments.Fig. 1. Topological mutations in SHaPrP. A. Schematic diagram of the PrP showing the positio
(TMD), glycosylphosphatidylinositol signal sequence (GPI), and the mutations studied. 1. Pr
contain amino acid substitutions alanine to arginine at position 2 and asparagine to arginine
at position 4 and tryptophane to glycine at position 7. 3. ΔSTEmutation is constructed by dele
which contains amino acid substitutions lysine and histidine to isoleucines at positions 110 an
113, 115 and 118, the A120L contains a single amino acid substitution alanine to leucine at po
residues 94 to 188 are from hamster PrP and contains the single amino acid substitution glycin
position 231, thereby deleting the GPI signal peptide. The positions of the epitopes for anti-P
based on in vitro translation studies is shown [35,37,38,56]. +++ Indicates an almost exclusiv
increase versus the wild type PrP; +/− indicates no change from the wild type PrP; and − inAll samples were immunoprecipitated with either PrP, Bcl-2 or Bax
antibodies or antisera (dilution of 1/100) in 1× RIPA buffer (10 mM
sodium Phosphate pH 7.4, 150 mM NaCl, 0.2% NP-40), 0.9% bovine
serum albumin and protein-A Sepharose [48]. The samples were
separated on 15% SDS-PAGE and either submitted directly to auto-
radiography for in vitro translated proteins or transferred to PVDF
membranes for western blotting.
2.12. Statistical evaluations
Statistical analyses were carried out by performing analysis of
variance (ANOVA) followed by Tukey's post hoc test using Statview
software (SAS Institute Inc., Cary, NC). The Fisher value (F-value) and
degrees of freedom (DF) (υ1,υ2) are indicated in the ﬁgure legends for
the ANOVA test. When indicated, a student T-test or a two-way
ANOVA was performed using Statview software. A pb0.05 was
considered to indicate a statistically signiﬁcant difference.
3. Results
3.1. Expression and topology of the various PrP constructs in MCF-7 cells
To determine which form and the location of the anti-Bax function
of PrP as a step to help eventually decipher the mechanism by which
PrP prevents Bax activation, we used several Syrian hamster PrP
mutant cDNAs that have been shown through cell free translocation
assays to favour either the secPrP, NtmPrP or CtmPrP topology (Fig. 1A).
Based on in vitro translation assays in the presence of dog pancreatic
microsomes, the ΔSTE and MH2M G123P generate almost uniquely
SecPrP while N4 A120L and N7a A120L generate mostly NtmPrP and
CtmPrP, respectively (Fig. 1B). The KH→II, AV3 and A120L make higher
levels of CtmPrP but do generate a bit of NtmPrP and low levels of SecPrP.
The Opn-PrP, Prl-PrP, and PrPΔGPI generate mostly SecPrP but make a
small amount of NtmPrP and CtmPrP. The N7a ΔSTE generates only a
very small amount of SecPrP but no NtmPrP or CtmPrP.
We chose to speciﬁcally activate Bax by EGFP-Bax overexpression
because, in contrast to an apoptotic insult, it does not activate other
cell death pathways that PrP may not inhibit. We transferred the PrP
cDNAs into the bigenic pBudCE4.1 vector, where EGFP or EGFP-Bax isns of signal peptide (SP), stop transfer effector sequence (STE), transmembrane domain
l-PrP and Opn-PrP contain SP of prolactin and osteopontin, respectively. 2. N4 mutants
at position 3, and N7a mutants contain amino acid substitutions leucine to aspartic acid
ting the STE, amino acids 104–112. 4.Mutations within the STE and TMD include KH→II,
d 111, the AV3mutation contains amino acid substitutions alanines to valines at residues
sition 120, and the MH2M G123P is a mouse-Syrian hamster chimeric protein in which
e to proline at position 123. 5.ΔGPImutation is constructed by truncatingWT SHaPrP at
rP antibodies R155, 3F4, and 13A5 are indicated. B. The expected PrP topology predicted
e topology; ++ indicates a signiﬁcant increase in the topology; + indicates insigniﬁcant
dicates an absence of the topology.
Fig. 2. Expression of PrP mutants in N2a and MCF-7 cells. A. Western blot of NP-40
soluble and NP-40 insoluble PrP proteins extracted from pBud-EGFP/PrP-transfected
N2a cells with the 3F4 or 13A5 antibodies. The blots were stripped and reprobed with
anti-GFP and anti-β-actin antibodies to control for transfection efﬁciencies and protein
load, respectively. B. Western blot of NP-40 soluble and NP-40 insoluble PrP proteins
extracted from pCep4βPrP transfected MCF-7 cells with the 13A5 antibodies. The blots
were stripped and reprobed with anti–GFP and anti–β–actin antibodies to control for
transfection efﬁciencies and protein load, respectively. *Indicates a non–speciﬁc protein
immunoreactivity to the 13A5 antibodies. C. Western blot with 3F4 antibodies of PrP
proteins extracted from pBud-EGFP-PrP, A120L, or N7a A120L-transfected cells
untreated or treated with Endo H or PNGase F.
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mutants are expressed under the CMV promoter, and transfected
the pBud constructs into MCF-7 cells since PrP has anti-Bax activity
in these cells. Low CMV promoter activity and transfection
efﬁciency in MCF-7 cells result in difﬁculty to detect SHaPrP
expression from pBudCE4.1-transfected cells. To conﬁrm that each
pBudCE4.1 construct efﬁciently expresses SHaPrP and mutant
proteins from the CMV promoter, we transfected N2a cells and
extracted the proteins in NP-40 lysis buffer, as this is a good buffer
to extract membrane proteins. We also re-extracted NP-40 insoluble
proteins with 2% SDS as a precaution against the loss of PrP protein
in the NP-40 insoluble fraction. We performed western blot
analyses to assess SHaPrP expression with the 3F4 or 13A5
antibodies that do not detect endogenous mouse PrP expression.
Both WT and mutant PrP were present in the NP-40 detergent
soluble and insoluble fraction. The detergent insolubility is not
representative of the disease-associated PrP as it occurs with WT
PrP. WT SHaPrP is highly expressed and easily detected with the
3F4 anti-PrP109–112 antibody in N2a cells (Fig. 2A). The KH→II and
ΔSTE mutants are not recognized by the 3F4 as expected since these
mutants lack the epitope. Nevertheless, all mutants, with the
exception of the A120L mutant, are recognized strongly with the
hamster-speciﬁc 13A5 anti-SHaPrP138–141 antibody.
To conﬁrm the expression and stability of these proteins in MCF-7
cells, we subcloned the SHaPrP and SHaPrP mutants into the
episomal pCep4β construct, which also contains the CMV promoter
but can express 50–100 copies of cDNA per cell. Similar to our
observation with the pBud constructs in N2a cells, PrP is expressed
from all constructs (Fig. 2B). The expression proﬁle is almost identical
to that observed in N2a cells except for the N4 A120L NtmPrP-
encoding construct which generates less mature PrP in MCF-7 cells
than in N2a cells. In both cell types, the transmembrane PrP-
encoding constructs generate less protein than the SecPrP-encoding
constructs.
The proﬁle of the immunodetected SHaPrP forms conﬁrms that
SecPrP-encoding constructs (WT SHaPrP, MH2MG123P, ΔSTE, Opn-PrP
and Prl-PrP) all express the three expected PrP species of immature
and mature glycosylated PrP in N2a and MCF-7 cells (Fig. 2A and B).
Deglycosylation shows Endo H sensitivity of the lower band as
expected for high mannose glycosylated proteins, and PNGaseF
sensitivity of all three major protein bands (Figs. 2C and 3B).
To fully assess PrP's topology inMCF-7 cells, total membranes were
isolated from transfected cells, and submitted to PK digestion before
protein extraction and deglycosylation. A schematic diagram in Fig. 3A
shows the expected protected epitopes and the size of the protected
protein fragments for lumenal, NtmPrP and CtmPrP proteins. Proteinase
K treatment of isolated membranes from WT PrP or MH2M G123P-
transfected MCF-7 cells reveal that the full length deglycosylated PrP
is lumenal as it is protected from protease digestion (Fig. 3B). Not all
PrP is protected because the membranes also contain plasma
membrane, which should have some GPI-anchored PrP. Alternatively,
the membranes could contain inside-out vesicles. The additional 3F4-
positive and 13A5-positive lower MW PrP fragments present after the
deglycosylation of the total membrane proteins, correspond to the N1
and C1 fragments of PrP generated through endogenous proteolysis
[49]. These are lumenal since they are protected from proteinase K
digestion (note that the absence of N1 in MH2M G123P is likely due to
low expression). The addition of Triton X-100 detergent to break down
the membranes eliminates the protection against proteinase K of
SecPrP and C1-SecPrP but not N1-SecPrP. Overall, these results indicate
that the SecPrP-encoding constructs generate PrP that is synthesized
normally through the secretory pathway.
The NtmPrP-encoding construct, N4A120L, generates a 16 kDa
protein fragment after the proteinase K digestion of membranes
(Fig. 3B). The protected protein fragment is detected with 3F4 but not
with 13A5, as expected. The size is consistent with either the retentionof the signal peptide or a slower migration on SDS-PAGE because the
N-terminal portion of PrP is highly acidic. In contrast to the in vitro
topological assays, N4A120L also generates lumenal full length SecPrP.
Furthermore, while the Triton X-100 detergent eliminates protection
against proteinase K of the full length PrP, it does not eliminate the
protection against the NtmPrP isoform. This indicates that this
fragment becomes resistant to detergents in a manner similar to
that of transmissible PrP and CHO-transfected A120L and L129 PrP
Fig. 3. Topology of PrP mutants in MCF-7 cells. A. Schematic diagram of the topology and 3F4 and 13A5 epitopes on CtmPrP, NtmPrP and lumenal SecPrP. The expected size and the
protected epitopes after proteinase K digestion of membranes are indicated for each topology on the right hand side panel. B. Western blot analyses with 3F4 and 13A5 anti-PrP
antibodies of membrane fractions prepared fromMCF-7-transfected cells that were untreated (−), treated without or with 0.25 mg/mL proteinase K after PNGaseF deglycosylation in
the absence or presence of Triton X-100 detergent.
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some transmembrane NtmPrP but it also makes signiﬁcant SecPrP.
We also veriﬁed the topology of CtmPrP encoded KH→II and AV3
in vivo. The KH→II protein does not contain the 3F4 epitope so we
show here the AV3. The AV3 construct generates SecPrP, although to a
lesser extent than the SecPrP-encoding constructs (Fig. 3B) and a
16 kDa 13A5-positive and 3F4-negative proteinase K protected
protein fragment that is consistent with CtmPrP that has retained
the GPI signal peptide. The N7a A120L and A120L CtmPrP constructs
were not investigated in the topological assays because of low
expression in MCF-7 cells, even from the pCep4β construct (Fig. 2B).
These two mutants generate a PrP form that migrates with immature
PrP and is Endo-H and PNGase F-resistant, indicating that this
protein is not glycosylated (Fig. 2C). Given that the size of the A120L
protein is slightly higher than the PNGase F-deglycosylated SHaPrP
(Fig. 2C), is not glycosylated as are AV3 and KH→II (Fig. 2C), and runs
slightly higher than KH→II in the cell free translocation system [35],
this protein resembles more SP-CyPrP than CtmPrP. The N7a A120L,
has an additional protein species that is sensitive to both Endo H andPNGase F treatment conﬁrming that it is glycosylated in the
immature form (Fig. 2C). The CyPrP-encoding construct, N7a ΔSTE,
encodes a single PrP protein that is of slightly higher molecular mass
than the PrPΔGPI (Fig. 2B) and is not glycosylated, indicating that
this protein has retained its GPI-signal peptide and has not
translocated into the ER as expected for SP-CyPrP [28]. Consistently,
this protein is entirely degraded by the proteinase K indicating the
absence of lumenal PrP (Fig. 3B). Because of the ability of the GPI
signal peptide sequence to interact strongly with membranes, this
form attaches to the membrane fraction although unlike previously
reported, we do not see integration as a CtmPrP form [51]. The
PrPΔGPI encodes one main protein that has a size consistent with no
glycosylation and the absence of the N- and C-terminal signal
peptides (Fig. 2A and B).
Together, these experiments conﬁrm the expression and topology
of PrP mutants in MCF-7 cells, but show that in vivo, a relatively large
amount of lumenal Sec-PrP is generated from both the CtmPrP and
NtmPrP-encoding constructs. This has also been reported for CtmPrP in
transgenic mouse brain microsomes [37,50].
Fig. 4. Cytotoxicity and anti-Bax activity of SecPrP, CyPrP and transmembrane PrP in
MCF-7 cells. A. Percentage cell death in MCF-7 cells transfected with pBud-EGFP/WT or
mutant PrPs. The data represent the mean and s.e.m. of three independent experiments
with 300 cells counted per experiment. ANOVA: DF=(12,26) and F-value=2.263. B.
Percentage cell death in MCF-7 cells transfected with pBud-EGFP-Bax/WT or mutant
PrPs. Data represent the mean and s.e.m. of four independent experiments with 50 cells
counted per experiment. ANOVA: DF=(12,41) and F-value=20.463. ⁎ indicates a pb0.05
statistically signiﬁcant difference between the vector control and the mutant for A and
B. The topology from IVT experiments (IVT topo.) [35,37] and from isolated membranes
in MCF-7 (Fig. 3B) (MCF-7 topo.) is indicated. C. Table comparing the anti-Bax function
of PrP mutants expressed from either pBud-EGFP-Bax or pCepP4β constructs.
+ indicates an anti-Bax function exerted by the PrP species; − indicates a loss of anti-
Bax function from the co-expression of PrP. ANOVA: DF=(5,17) and F-value=14.682.
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protect against Bax-mediated cell death in MCF-7 cells
Only the KH→II SHaPrPmutant shows slight toxicity inMCF-7 cells
(Fig. 4A). Expression of N-terminally EGFP-tagged pro-apoptotic Bax
(EGFP-Bax) in MCF-7 cells results in 58% cell death within 20 h
(Fig. 4B). The co-expression of WT SHaPrP with EGFP-Bax decreases
cell death to approximately 31%. The PrPΔGPI, the SecPrP-encoding
constructs (MH2M G123P, ΔSTE, Opn-PrP, Prl-PrP), and the SP-CyPrP
constructs (N7a ΔSTE and A120L) (Figs. 2C and 3B), protect against
Bax-mediated cell death to a similar extent as WT PrP. However, the
CtmPrP and NtmPrP constructs (AV3, N4 A120L, KH→II, N7a A120L and
N4 A120L) do not prevent Bax-mediated cell death despite the fact
that thesemutantsmake a high amount of SecPrP (Figs. 3B and 4B). The
possibility that lower expression levels may be responsible for the loss
of anti-Bax function in these mutants can be excluded since (1) the
N7aΔSTE protects against Bax despite similar low levels, and (2) we
compared the anti-Bax function of PrP mutants expressed in the low
expression vector, pBud, with that of the high expression episomal
pCep4β construct, and both generated identical results (Fig. 4C). TakenFig. 5. Cytotoxicity and anti-Bax activity of SecPrP, CyPrP and transmembrane PrP in
primary human neuron cultures. A. Percentage cell death in primary human neurons
transfected with pBud-EGFP/WT or mutant PrPs. The data represent the mean and s.e.
m. of three independent experiments with 100 cells counted per experiment. ANOVA:
DF=(12,29) and F-value=1.754. B. Percentage cell death in primary human neurons
transfected with pBud-EGFP-Bax/WT PrP or mutant PrPs. Data represent the mean and
s.e.m. of ﬁve independent experiments with 70 cells counted per experiment. ANOVA:
DF=(12,28) and F-value=7.384. ⁎ indicates a pb0.05 statistically signiﬁcant difference
between the vector control and the mutant.
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mediated cell death even if they produce SecPrP. The results thus imply
that in addition to lumenal, GPI-anchored or secreted PrP, SecPrP
generates an additional form of PrP that is protective.
3.3. SecPrP, CyPrP, and NtmPrP, but not CtmPrP, protect against
Bax-mediated cell death in primary human neurons
Because prion diseases affect the central nervous system (CNS), we
repeated the functional assays in primary cultures of human neurons.
In these experiments, we are limited to single cell analyses since
these primary neurons cannot be transfected or infected with high
efﬁciency. Furthermore, high endogenous levels of human PrP whose
epitopes are conserved in hamster PrP exclude the possibility of
investigating expression or topology. Only KH→II and PrPΔGPI are
slightly toxic to human neurons (Fig. 5A). As observed before, WT
SHaPrP protects human neurons against Bax-mediated cell death.
The protection against Bax in human neurons is not as strong as
previously demonstrated [15] because, in these experiments, we used
the more toxic EGFP-Bax in order to easily detect transfected cells.
However, similar to observations in MCF-7 cells, all CtmPrP-encodingFig. 6. Anti-Bax function of non-membrane attached extracellular PrP. A. Western blots of R1
cells with 13A5 antibodies. B. Percentage of cell death in pBud-EGFP-Bax-transfected MCF-7
pBud-EGFP-Bax and pCep4β-PrP, CyPrP or ΔGPI. The data represent the mean and s.e.m. of
pb0.01 statistically signiﬁcant difference between pBud-EGFP-Bax and pBud-EGFP-Bax wit
MCF-7 cells and the increasing amounts of rPrP added into the media of pBud-EGFP-Bax-tra
cells incubatedwith the PrP-immunodepleted (+) or non-treated (−) recuperated cell culturem
and s.e.m. of three independent experiments. ⁎ indicates a pb0.01 statistically signiﬁcant d
Student T-test. Two-way ANOVA: PrP depletion or not DF=(1,10) and F-value=4.850, contro
and control or ΔGPI DF=(1,10) and F-value=3.329. E. Western blot of PrP with 3F4 in EGFP (C
(−) cell culture media.constructs, including the A120L, lose their anti-Bax function, while
the secreted and cytosolic PrP-encoding constructs maintain their
anti-Bax function (Fig. 5B). However, unlike the MCF-7 cells, the one
construct that should favour NtmPrP topology, N4a A120L retains its
anti-Bax function. This could be due to a different topology of the
protein in human neurons since we observe the expected NtmPrP
proﬁle in MCF-7 cells but not in N2a cells, where this construct
generates SecPrP instead of NtmPrP (Fig. 2A and B).
3.4. Non-membrane attached SecPrP has only a slight anti-Bax function in
MCF-7 cells
Because lumenal and GPI-anchored SecPrP does not prevent Bax-
mediated cell death in the presence of CtmPrP or NtmPrP in MCF-7 cells,
we investigated if non-membrane attached extracellular PrP has an
anti-Bax function. First, we examined if SecPrP was GPI-anchored or
released in the media. PrP was immunoprecipitated from cell culture
media from transfected cells with R155 anti-PrP36–56 and the
immunoprecipitated PrP was detected with 13A5 anti-PrP antibody
by western blots (Fig. 6A). Non-membrane attached SecPrP is present
inWT PrP, MH2M G123P, ΔSTE, Prl-PrP, Opn-PrP and ΔGPI-transfected55 immunoprecipitated PrP from the extracellular milieu of pBud-EGFP/PrP-transfected
cells incubated with increasing amounts of rPrP or in MCF-7 cells co-transfected with
three independent experiments. ANOVA: DF=(9,20) and F-value=15.733. ⁎ indicates a
h PrP, CyPrP or ΔGPI. C. Western blot of cellular and extracellular PrP from transfected
nsfected MCF-7 cells. D. Percentage of cell death in pBud-EGFP-Bax-transfected MCF-7
edia from EGFP (control) orΔGPI-transfectedMCF-7 cells. The data represent themean
ifference between the control and ΔGPI without PrP immunodepletion assessed with a
l or ΔGPI DF=(1,10) and F-value=10.375, and interaction between PrP depletion or not
ontrol) or ΔGPI-transfected MCF-7 cells and in PrP-immunodepleted (+) or non-treated
2009D.T.S. Lin et al. / Biochimica et Biophysica Acta 1783 (2008) 2001–2012cells, but is absent from cells transfected with the transmembrane
constructs.
To assess if extracellular non-membrane attached SecPrP has an
anti-Bax function, we treated Bax-transfected MCF-7 cells with
various concentrations of puriﬁed recombinant PrP (rPrP) (Fig. 6B).
The recombinant PrP does not have a signiﬁcant protection against
Bax-mediated cell death. A western blot analysis of non-membrane
attached SecPrP from PrP-transfected MCF-7 cells shows that the50 pM concentration of rPrP added to EGFP-Bax-transfected cells is
equivalent to that normally produced from PrP-transfected cells
(Fig. 6C). Adding conditioned media from PrPΔGPI-transfected cells
to EGFP-Bax-transfected cells shows a small but statistically
signiﬁcant protection against Bax-mediated cell death (Fig. 6D). To
ensure that this protective effect is directly attributed to the non-
membrane attached PrPΔGPI, we immunodepleted PrPΔGPI from
the conditioned media with R155 anti-PrP. Western blot analyses
conﬁrm the complete immunodepletion of PrPΔGPI after treatment
(Fig. 6E), and the immunodepleted media lose the anti-Bax function
(Fig. 6D). Together, these results indicate that non-membrane
attached secreted PrP can prevent Bax-mediated cell death.
However, the effect is weak and cannot account completely for
the protection seen with SecPrP-encoding constructs.
3.5. CyPrP decreases considerably in transmembrane-encoding PrP
constructs and CyPrP rescues MCF-7 cells and human neurons
against the loss of anti-Bax function in CtmPrP
Since non-membrane attached SecPrP did not yield a signiﬁcant
level of anti-Bax function, it is possible that SecPrP-encoding
constructs protect by generating CyPrP. Indeed, subcellular fractiona-
tion experiments show that WT and MH2M G123P generate CyPrP
whereas transmembrane-encoding PrP constructs, N4A120L,
SH3AV3, KH→II, and N7aA120L do not (Fig. 7A). Possible aggregation
or attachment of CyPrP to the membranes can be excluded since
there is no more NP-40 insoluble protein from transmembrane PrP-
encoding constructs than from SecPrP constructs (Fig. 2) and we
could not extract CyPrP from membranes with sodium carbonate
treatments (not shown). Co-transfection of KH→II, SHaAV3,
N7aA120L and N4A120L with CyPrP results in anti-Bax function
(Fig. 7B). Furthermore, co-transfection of KH→II and SHaAV3 CyPrP
mutants with the corresponding CyPrPKH→II and SHaAV3-encoding
mutant constructs also rescues against the loss of anti-Bax function
(Fig. 7B). Expression of the mutant CyPrP proteins is shown in Fig.
7C. Please note that the N4a A120L and N7a A120L CyPrPs could not
be made since the mutation is in the N-terminal signal peptide that
is absent in CyPrP.
CyPrP also rescues against the loss of anti-Bax function in KH→II,
AV3, A120L and N7a A120L mutants in primary human neurons.
Therefore, the loss of anti-Bax function from transmembrane-
encoding PrP constructs in human neurons is the result of a loss of
CyPrP. Together, these results indicate that the CyPrP is the major
form of PrP that protects against Bax-mediated cell death.
3.6. PrP does not co-immunoprecipitate with Bax
We have shown in this study that the PrP species that is most
protective against Bax-mediated cell death is localized in the cytosol,
where the pro-apoptotic Bax is also localized. To further assess ifFig. 7. CyPrP rescues the loss of anti-Bax function in transmembrane-encoding PrP
constructs. A. Western blot of membrane and cytosolic fractions of PrP proteins
extracted from MCF-7 cells transfected with pCepP4β-WT or mutant PrPs and treated
with epoxomycin and Brefeldin A. The blots were stripped and reprobed with Bip to
conﬁrm the absence of membrane proteins in the cytosolic fractions. ⁎ indicates a non-
speciﬁc protein immunoreactivity to the Bip antibodies. B. Table comparing the anti-
Bax function of WT and mutant PrPs in the absence (−) or presence of normal CyPrP
(CyPrP rescue) or mutant CyPrP rescue (CyPrPMut.). ANOVA: DF=(13,24) and F-
value=7.151. C. Western blot of proteins extracted from pCep4β-WTSHaCyPrP,
pCep4β–CyKH→II, pCep4β–CySHaAV3, or mock transfected cells with 13A5 antibodies.
D. Percentage cell death in primary human neurons transfected with only pBud–EGFP–
Bax/WT PrP or mutant PrPs (dark bars) or co–transfected with pBud–EGFP–Bax/WT PrP
or mutant PrPs and pCep4b-CyPrP (light bars). Data represent the mean and s.e.m. of
three independent experiments with 30 cells counted per experiment. ANOVA: DF =
(11,23) and F–value = 11.321. *indicates a pb0.05 statistically signiﬁcant difference
between the pBud-EGFP-Bax vector control and the mutant. § indicates a pb0.05
statistically signiﬁcant difference between the mutant and the mutant co-transfected
with pCepP4β-CyPrP pair.
Fig. 8. Co-immunoprecipitation of prion protein with Bax and Bcl-2. A. Autoradiogram of 35S-methionine labelled in vitro translated proteins immunoprecipitated with polyclonal
anti-Bax N-20, polyclonal anti-Bcl-2 (pBcl-2) or polyclonal anti-PrP (R155) antisera. B–D. Western blot analysis of PrP with monoclonal 3F4 (B), Bcl-2 with monoclonal anti-Bcl-2
(mBcl-2) (C), or Bax with 2D2 (D) of co-immunoprecipitation of pure recombinant Bax with N-20, Bcl-2 with pBcl-2 or PrP with R155. The last lane represents input protein for the
immunoprecipitation. Beads represent a control without antibody. E. Western blot analyses of Bax (N-20). PrP (R155) or Bcl-2 (pBcl-2) immunoprecipitates from human brain protein
extracts with antibodies 3F4 for PrP, 2D2 for Bax or mBcl-2 for Bcl-2.
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change, we assessed PrP-Bax interaction by immunoprecipitation. We
could not detect co-immunoprecipitation of in vitro translated PrP or
CyPrP with either Bax or Bcl-2 (Fig. 8A). Similarly, using PrP, Bax, and
Bcl-2 puriﬁed from Escherichia coli (E. coli), we could not detect co-
immunoprecipitation between these proteins (Fig. 8B–D). Further-
more, we exclude the possibility that PrP and Bax interact in a human
brain protein extract (Fig. 8E). We detect co-immunoprecipitation of
Bcl-2 with Bax N-20 antisera in the brain protein extract, but this
interaction is not conﬁrmed with the polyclonal Bcl-2 antisera
immunoprecipitation (Fig. 8E). Similarly, Bcl-2 and Bax interactions
are not observed using in vitro translated or recombinant Bax and Bcl-
2 proteins (Fig. 8A). Together, these results do not support a direct
interaction between PrP and Bax for PrP's inhibition of Bax
conformational change.
4. Discussion
PrP is a secretory glycoprotein that achieves several topological
forms and subcellular localizations. We have previously identiﬁed that
both SecPrP and CyPrP can prevent Bax-mediated cell death [15,27].
PrP prevents the initial conformational change that is responsible for
converting cytosolic Bax into its mitochondrial localized pro-apoptotic
form [16]. These results raised the question as to whether PrP
inhibited Bax activation from various subcellular localizations and in
different topological forms. Our results show that CyPrP is the
predominant anti-Bax form of PrP. This conclusion is based on several
observations. First, we have excluded all other topological forms of PrP
as possible anti-Bax proteins. In PrP mutant constructs that generateSecPrP and transmembrane forms of PrP, in either the CtmPrP or NtmPrP
orientation, there is no anti-Bax function. Second, we excluded a
strong anti-Bax function from secreted non-membrane attached PrP
that occurs in SecPrP-encoding constructs. The small amount of anti-
Bax function in non-membrane attached PrP is likely the result of PrP
interaction with a receptor. While several studies have shown a
neuroprotective function for GPI-anchored PrP through interaction
with antibodies or a peptide ligand [52–54], no one has reported that
non-membrane attached PrP interacts with a receptor to transduce a
neuroprotective signal. Third, mutants that lack anti-Bax activity do
not produce CyPrP. Fourth, we can rescue PrP's anti-Bax function
when co-transfecting the PrP mutants that have lost the anti-Bax
function with a normal CyPrP-encoding construct. Furthermore, we
exclude the possibility that mutant PrPs lose their anti-Bax function
because of a structural alteration by also showing that mutant CyPrPs
rescue against the loss of anti-Bax function in the corresponding
mutant PrP.
An interesting side observation that resulted from these experi-
ments is that the PrP topology is regulated differently in cells and in
cell free systems. Indeed, whereas the PrP mutant constructs have
beenwell characterized to principally generate CtmPrP, NtmPrP or SecPrP
from in vitro translations in the presence of dog pancreatic micro-
somes [35,37,55,56], the expression of PrP from these same constructs
in MCF-7 cells generated mostly SecPrP and only a small amount of
CtmPrP or NtmPrP. Others have observed SecPrP generated from
transmembrane-generating PrP constructs [37,50,57]. Furthermore,
the A120L construct generates different PrP isoforms in N2a and MCF-
7 cells and the function varies in MCF-7 and human neurons
indicating that the A120L can give rise to different topologies in
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composition of a membrane can affect the topology of polytopic
proteins [58]. Furthermore, proteins involved in translocation are also
very important for PrP translocation and topology [38,59,60]. There-
fore, both lipid composition of membranes and translocon protein
composition could explain why some PrP mutations have different
topologies when synthesized in different environments.
The inability of the transmembrane-generating PrP mutants to
make CyPrP is also intriguing. However, this agrees with our results
that show that all familial PrP mutations associated with Creutzfeldt–
Jakob disease have defective retrotranslocation [32]. Similar to our
previous ﬁndings, the effect is likely dominant since in human
neurons, which express considerable amounts of endogenous PrP and
usually make CyPrP, the transmembrane-generating PrP mutants also
fail to prevent Bax-mediated cell death and can be rescued by co-
transfection of CyPrP. Much more difﬁcult experimentation will be
required to understand this observation as there are several
possibilities. One would be that the structure of PrP might be
important for normal retrotranslocation. However, since retrotranslo-
cated proteins utilize the same mechanism as in translocation, and
mutant PrPs go through the secretory pathway, the mutant PrP would
have to undergo its structural change after its initial translocation in
the lumen of the endoplasmic reticulum. Another is that a speciﬁc
protein involved in PrP retrotranslocation cannot function with these
PrP mutants. However, this does not explain the dominant effect.
Therefore, a third possibility would be that the mutant protein alters
the retrotranslocation machinery so that proteins cannot be retro-
translocated normally.
Given that the PrP mutant constructs do not generate a signiﬁcant
amount of CtmPrP or NtmPrP, it is thus not surprising that we do not see
toxicity when expressing these in MCF-7 cells. The cytotoxicity of the
KH→II construct is relatively small and is probably not due to the
production of CtmPrP since the AV3 mutant generates CtmPrP in the
absence of cytotoxicity. Our observations are consistent with previous
ﬁndings in transgenic mice where expression of CtmPrP at 0.25 to 0.5
fold ofWT SHaPrP showed no clinical signs and remained healthy [37].
However, overexpression of two to four fold CtmPrP induced astro-
gliosis and neurodegeneration in these mouse brains. It is possible
that long-term expression of the CtmPrP could cause some toxicity.
Nevertheless, a slight toxicity is not responsible for the loss of anti-Bax
function since the loss of anti-Bax function in these mutants was
rescued by co-expressing CyPrP.
Despite showing that the CyPrP is the predominant anti-Bax form
of PrP, we have not observed a direct interaction between CyPrP and
Bax in vitro and in vivo. Similarly, we did not see a direct interaction
between Bcl-2 and Bax. Previous studies where direct Bax/Bcl-2
interactions were observed involved the use of fusion proteins in the
yeast 2-hybrid system [61,62] and hemagglutinin- or Myc-tagged
proteins in co-immunoprecipitation experiments [63]. In addition, in
recent co-immunoprecipitation and Bax oligomerization studies done
by Dlugosz et al. [64], it was shown that Bcl-2 and Bax do not interact
directly in the absence of an apoptotic stimulus. These results
therefore conﬁrm those of Kurschner and Morgan who found Bcl-2-
PrP interaction in the yeast 2-hybrid system but could not conﬁrm
interaction by co-immunoprecipitations [61,62]. We have previously
excluded the possibility that other Bcl-2 proteins are necessary for
PrP's anti-Bax function [20]. These results thus suggest that a cytosolic
but Bcl-2 family independent pathway is regulated by PrP to inhibit
Bax activation.
These results also imply that the retrotranslocated PrP is not only
destined todegradationby theproteasomebut serves a survival function.
Other studies on EGFR, clusterin, and cholera toxin have proposed
retrotranslocation as a pathway to bring secretory proteins into the
cytosol, where they serve a physiological function instead of being
degraded [65–67]. Such a function for PrP could be important in the
protection of neurons and MCF-7 cells against Bax-mediated cell death.Acknowledgments
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